UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OMB APPROVAL

OMB Number: 3235-0076

Estimated average burden hours per response 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous	Names None	Entity Type
·			
0001402328	Mountai		X Corporation
Name of Issuer	Business Solution	•	Limited Partnership
Sunshine Biopharma, Inc		s, Inc.	Limited Liability Company
Jurisdiction of Incorporation	on/Organization		General Partnership
COLORADO			Business Trust
Year of Incorporation/Orga	anization		Other (Specify)
X Over Five Years Ago			
Within Last Five Years	(Specify Year)		
Yet to Be Formed			
2. Principal Place of Bus	iness and Contact Informa	ition	
Name of Issuer			
Sunshine Biopharma, Inc			
Street Address 1		Street Address 2	
6500 TRANS-CANADA HI	GHWAY, 4TH FLOOR		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
POINTE-CLAIRE	QUEBEC, CANADA	H9R 0A5	(514) 426-6161
3. Related Persons			
Last Name	First Name		Middle Name
Slilaty	Steve		N.
Street Address 1	Street Address 2	2	
6500 TRANS-CANADA HI	GHWAY,		
4TH FLOOR City	State/Province/0	Country	ZIP/PostalCode
POINTE-CLAIRE	OUEBEC, CANA		H9R 0A5
Relationship: X Ex	ecutive Officer X Dir	ector Promote	er
Clarification of Response ((if Necessary):		
President, Chief Executive O	officer and Chairman		
Last Name	First Name		Middle Name
Merzouki	Abderrazzak		
Street Address 1	Street Address 2	2	
6500 TRANS-CANADA HI 4TH FLOOR	GHWA1,		
City	State/Province/0	Country	ZIP/PostalCode
POINTE-CLAIRE	QUEBEC, CANA		H9R 0A5
Relationship: X Ex	ecutive Officer X Dir	ector Promote	er
Clarification of Response ((if Necessary):		
Chief Operating Officer			
Last Name	First Name		Middle Name
Sebaaly Street Address 1	Camille Street Address 2)	
6500 TRANS-CANADA HI		<u>-</u>	
4TH FLOOR	OII111,		
City	State/Province/0	Country	ZIP/PostalCode
POINTE-CLAIRE	QUEBEC, CANA	.DA	H9R 0A5

Relationship: X Executive Off	cer Director Promote	r
Clarification of Response (if Necessa	ry):	
Chief Financial Officer and Secretary		
Last Name Kiderchah Street Address 1 6500 TRANS-CANADA HIGHWAY, 4TH FLOOR City POINTE-CLAIRE Relationship: Executive Off	First Name Rabi Street Address 2 State/Province/Country QUEBEC, CANADA icer X Director Promote	ZIP/PostalCode H9R 0A5
Clarification of Response (if Necessa	ry):	
Last Name Natan Street Address 1 6500 TRANS-CANADA HIGHWAY, 4TH FLOOR City POINTE-CLAIRE Relationship: Executive Off		ZIP/PostalCode H9R 0A5
Clarification of Response (if Necessa	ry):	
Last Name Keller Street Address 1 6500 TRANS-CANADA HIGHWAY, 4TH FLOOR City POINTE-CLAIRE Relationship: Executive Off Clarification of Response (if Necessa		Middle Name ZIP/PostalCode H9R 0A5
4. Industry Group		
Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Sel Business Services Energy Coal Mining Electric Utilities	Commercial Construction REITS & Finance	Retailing Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel Other

Energy Conservation	
Environmental Services	
Oil & Gas	
Other Energy	
5. Issuer Size	
Revenue Range	OR Aggregate Net Asset Value Range
No Revenues	No Aggregate Net Asset Value
\$1 - \$1,000,000	 \$1 - \$5,000,000
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000
Over \$100,000,000	Over \$100,000,000
X Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable
6. Federal Exemption(s) and Exclusion	n(s) Claimed (select all that apply)
Rule 504(b)(1) (not (i), (ii) or (iii))	X Rule 506(b)
Rule 504 (b)(1)(i)	Rule 506(c)
Rule 504 (b)(1)(ii)	Securities Act Section 4(a)(5)
Rule 504 (b)(1)(iii)	Investment Company Act Section 3(c)
	<u> </u>
	Section 3(c)(1) Section 3(c)(9)
	Section 3(c)(2) Section 3(c)(10)
	Section 3(c)(3) Section 3(c)(11)
	Section 3(c)(4) Section 3(c)(12)
	Section 3(c)(5) Section 3(c)(13)
	Section 3(c)(6) Section 3(c)(14)
	Section 3(c)(7)
7. Type of Filing	
X New Notice Date	e of First Sale 2022-03-10 First Sale Yet to Occur
Amendment	
8. Duration of Offering	
Does the Issuer intend this offering to la	st more than one year? Yes X No
9. Type(s) of Securities Offered (selec	t all that apply)
X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Ac	quire Another Security Mineral Property Securities
Security to be Acquired Upon Exerci	
Other Right to Acquire Security	
10. Business Combination Transaction	n

☐Yes ☐No

Is this offering being made in connection with a business merger, acquisition or exchange offer?	combination transaction, such as a
Clarification of Response (if Necessary):	
11. Minimum Investment	
Minimum investment accepted from any outside investor	\$ 0 USD
12. Sales Compensation	
Recipient	Recipient CRD Number None
Aegis Capital Corp.	15007
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
Street Address 1	Street Address 2
810 7TH AVE	18TH & 22ND FLOOR
City State/Province/Country	ZIP/Postal Code
NEW YORK NEW YORK	10019
State(s) of Solicitation All States Non-US/Forei	
	CT LDE LDC LFL LGA LHI LID
∐IL ∐IN ∐IA ∐KS ∐KY ∐LA ∐I	ME L MD L MA L MI L MN L MS L MO
MT NE XNV NH NJ NM XN	IY NC ND OH OK OR PA
RI SC SD TN TX UT	/T UA WA WV WI WY PR
13. Offering and Sales Amounts	
Total Offering Amount \$ 7,998,699 USD	or Indefinite
Total Amount Sold \$ 7,998,699 USD	
Total Remaining to be Sold \$ 0 USD	or Indefinite
·	
Clarification of Response (if Necessary):	
AA lawastan	
14. Investors	
Select if securities in the offering have been or may laceredited investors, and enter the number of such reinvested in the offering.	
Regardless of whether securities in the offering have not qualify as accredited investors, enter the total nu invested in the offering:	
15. Sales Commissions & Finder's Fees Expenses	
Provide separately the amounts of sales commissions ar expenditure is not known, provide an estimate and check	
Sales Commissions \$ 960,000 USD Estimate	
Finders' Fees \$ 0 USD Estimate	
Clarification of Response (if Necessary):	
Includes non-accountable expense allowance of 2% of gross p	roceeds.
16. Use of Proceeds	

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to
any of the persons required to be named as executive officers, directors or promoters in response to Item 3
above. If the amount is unknown, provide an estimate and check the box next to the amount.

	\$ 0 USD Estimate
Clarification of Response (if Necessary):	
Signature and Submission	

Please verify the information you have entered and review the Terms of Submission below before signing and submitting this notice.

Terms of Submission

In submitting this notice, each identified issuer is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and
 undertaking to furnish them, upon written request, in the accordance with applicable law, the information
 furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes; or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not
 disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506
 (d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Sunshine Biopharma, Inc	/s/ Steve N. Slilaty	Steve N. Slilaty	Chief Executive Officer	2022-03-18

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.